158 related items for PubMed ID: 12226017
1. Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness.
Langley SJ, Holden J, Derham A, Hedgeland P, Sharma RK, Woodcock A.
Chest; 2002 Sep; 122(3):806-11. PubMed ID: 12226017
[Abstract] [Full Text] [Related]
2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P.
Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
[Abstract] [Full Text] [Related]
3. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
Ayres JG, Millar AB, Sykes AP.
Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
[Abstract] [Full Text] [Related]
4. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
Tonnel AB, Bons J, Legendre M, Prud'Homme A, Bugnas B, Evano-Celli I, Stuart AM.
Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
[Abstract] [Full Text] [Related]
5. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
Perruchoud AP, Lundback B, Yigla M, Sykes AP.
Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
[Abstract] [Full Text] [Related]
6. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma.
Lee DK, Haggart K, Currie GP, Bates CE, Lipworth BJ.
Br J Clin Pharmacol; 2004 Jul; 58(1):26-33. PubMed ID: 15206989
[Abstract] [Full Text] [Related]
7. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.
Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ.
Chest; 2005 Mar; 127(3):851-60. PubMed ID: 15764767
[Abstract] [Full Text] [Related]
8. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.
Currie GP, Fowler SJ, Wilson AM, Sims EJ, Orr LC, Lipworth BJ.
Thorax; 2002 Oct; 57(10):865-8. PubMed ID: 12324672
[Abstract] [Full Text] [Related]
9. Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children.
Lyttle B, Gilles J, Panov M, Emeryk A, Wixon C.
Can Respir J; 2003 Mar; 10(2):103-9. PubMed ID: 12687029
[Abstract] [Full Text] [Related]
10. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ, Currie GP, Lipworth BJ.
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[Abstract] [Full Text] [Related]
11. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.
Giannini D, Di Franco A, Bacci E, Dente FL, Taccola M, Vagaggini B, Paggiaro P.
Chest; 2000 May; 117(5):1319-23. PubMed ID: 10807817
[Abstract] [Full Text] [Related]
12. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate.
Fowler SJ, Orr LC, Sims EJ, Wilson AM, Currie GP, McFarlane L, Lipworth BJ.
Chest; 2002 Aug; 122(2):618-23. PubMed ID: 12171841
[Abstract] [Full Text] [Related]
13. Fluticasone propionate HFA-134a pressurized metered-dose inhaler in adolescents and adults with moderate to severe asthma.
Pinnas JL, Noonan MJ, Weinstein SF, Chervinsky P, Scott CA, Herje NE, Wu W, Crim C.
J Asthma; 2005 Dec; 42(10):865-71. PubMed ID: 16393726
[Abstract] [Full Text] [Related]
14. Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids.
Lumry WR, Conway MM, LaForce CF, Pearlman DS, Scott CA, Herje NE, Wu WW, Crim C.
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):51-9. PubMed ID: 16440533
[Abstract] [Full Text] [Related]
15. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
Kunka R, Andrews S, Pimazzoni M, Callejas S, Ziviani L, Squassante L, Daley-Yates PT.
Respir Med; 2000 Jun; 94 Suppl B():S10-6. PubMed ID: 10919680
[Abstract] [Full Text] [Related]
16. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT.
Clin Pharmacokinet; 2000 Jun; 39 Suppl 1():17-22. PubMed ID: 11140429
[Abstract] [Full Text] [Related]
17. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.
Houghton CM, Langley SJ, Singh SD, Holden J, Monici Preti AP, Acerbi D, Poli G, Woodcock A.
Br J Clin Pharmacol; 2004 Oct; 58(4):359-66. PubMed ID: 15373928
[Abstract] [Full Text] [Related]
18. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
Woodcock A, Williams A, Batty L, Masterson C, Rossetti A, Cantini L.
J Aerosol Med; 2002 Oct; 15(4):407-14. PubMed ID: 12581507
[Abstract] [Full Text] [Related]
19. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.
Dempsey OJ, Wilson AM, Coutie WJ, Lipworth BJ.
Chest; 1999 Oct; 116(4):935-40. PubMed ID: 10531156
[Abstract] [Full Text] [Related]
20. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
Respiration; 2005 Oct; 72 Suppl 1():20-7. PubMed ID: 15915009
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
